Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Zymeworks Inc.

NASDAQ: ZYME · Life Sciences · 7 alerts · CIK 1937653

Share price
$26.45Close, Nov 16
Market cap
$1.83B
Shares outstanding
69.03MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zymeworks Inc. filings on SEC EDGAR ↗

6:17 AM ET Form 4
Insider Selling

Zymeworks CSO Paul Andrew Moore Sells $1.04M of Stock

Paul Andrew Moore, CSO, sold 39,741 shares of Zymeworks Inc. at $26.04 to $26.14 a share (average $26.07) in 3 transactions, worth $1.04M in total on Nov 13, 2026. Shares held after the trade: 33,756 (-42.5%).

Value
$1.04M
Shares
39,741
Average price
$26.07
Role
CSO
Holding change
-42.5%
Trade date
Nov 13, 2026
6:14 AM ET 8-K
Stock Buyback

Zymeworks Announces $200M Stock Buyback

Zymeworks authorized a new $200 million share repurchase program through 2028, following the completion of its initial $125 million program. The company expects to spend approximately $140 million under this new authorization to reduce share count and return capital to shareholders.

Value
$200M
Term
through 2028
4:40 PM ET 8-K/A
M&A Deal

Zymeworks M&A Deal with Theravance Biopharma, Inc.

Zymeworks Inc. filed an amendment to its previous 8-K to provide historical and pro forma financial statements following its completed acquisition of Theravance Biopharma, Inc. The merger involved a cash payment of $17.00 per share plus a contingent value right (CVR) tied to the future monetization and commercial success of ampreloxetine. The cash portion of the deal was financed through $350 million in non-recourse notes from OMERS Life Sciences and existing cash reserves.

Counterparty
Theravance Biopharma, Inc.
4:10 PM ET 10-Q
Financial Results

Zymeworks Q3 2026 Results: Turns Profitable, Net Income $174M

Zymeworks Inc. reported a significant increase in total revenue to $256.5 million for the third quarter of 2026, primarily driven by $250.0 million in license and milestone revenue. The company achieved a net income of $173.7 million for the quarter, a substantial improvement from the $19.6 million net loss in the prior year period, despite an increase in operating expenses to $78.9 million.

Key figure
Net income $174M
4:08 PM ET 8-K
Financial Results

Zymeworks Financial Results

Zymeworks reported Q3 2026 financial results and significantly raised its full-year 2026 revenue guidance to $337M-$351M. The company highlighted the recent FDA approval of Ziihera for first-line GEA, which triggered a $250 million milestone payment from Jazz Pharmaceuticals, and the completion of its acquisition of Theravance Biopharma.

Term
Q3 2026

“We are entering the next phase of Zymeworks growth with a fundamentally stronger and more diversified business. The transformation of Zymeworks is becoming increasingly visible in our financial profile and in the breadth of opportunities available to us.”

Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks

“These advancements demonstrate the strategy we set out a year ago - to build a durable financial foundation through partnered and commercial assets, while maintaining the ability to create additional value through R&D, acquisitions, partnerships and disciplined capital allocation.”

Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks
6:07 AM ET 8-K
Licensing Deal

Zymeworks Licensing Deal with Roche Worth $813M

Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.

Value
$813M
Counterparty
Roche

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.